NEW YORK (GenomeWeb) – As part of its effort to focus on its molecular diagnostics business, PDI announced today that it has agreed to sell off its biomedical commercialization and marketing services business to Publicis Group for up to roughly $48 million.

PDI also said it will assume the name of its molecular diagnostics subsidiary, Interpace Diagnostics, and chance its Nasdaq trading symbol to IDXG. The sale is expected to close in the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.